FDA OK for laser surgery tool. Stock starting to surge. Here's the Release:
BIOLASE TECHNOLOGY, INC. Receives FDA Clearance to
Market New Advanced Laser Surgical System
Jul 24, 1997 11:30 AM Business Wire
SAN CLEMENTE, CALIF. (July 24) BW HEALTHWIRE -July 24,
1997--BIOLASE TECHNOLOGY, INC. (NASDAQ:BLTI) announced
today that it has received clearance by the U.S. Food
and Drug Administration to market its DermaLase(TM)
laser system for a broad range of dermatologicaland general surgical applications. <P>"We are excited that we are now able to offer our
DermaLase(TM) system to dermatologists and general
surgeons as it offers many benefits to the patient,"
said Donald A. La Point, President and CEO of BIOLASE.
"The DermaLase(TM) system can be used in a wide
variety of surgical indications, including incision,
excision, ablation, vaporization and coagulation
of soft tissue. We believe that the proprietary
technology incorporated in our DermaLase(TM) system,
which combines a very effective laser wavelength with
a unique air/water spray, results in improved
histological effects on tissue including reduced
tissue trauma and faster healing. As a result,
the DermaLase(TM) system is effective for scar
revision, removing tumors and cysts, performing
diagnostic biopsies and skin resurfacing, to note
just a few of the applications that may beperformed with the DermaLase(TM) system."
Dr. Lewis R. Eversole, professor of pathology
at the University of California, Los Angeles and
principal investigator for BIOLASE's domestic
clinical studies, stated, "The use of cool,
sterilized water during the cutting process yields
excellent results in dermatology, cosmetic,
reconstructive, oral and general surgeries.
One particular application -- skin resurfacing --
illustrates this point. Conventional laser surgery
can produce skin burns that take weeks or months
to heal. By contrast, skin treated with the
DermaLase(TM) system heals in substantially
shorter time."As the only laser system of which I am aware that
incorporates water assisted cutting, cooling and
hydration, DermaLase(TM) represents to the medical
specialist a surgical tool unique, flexible and
efficacious for multiple applications.
In addition, DermaLase(TM) cuts precisely with
minimum trauma to tissue. These characteristics
should be of great interest and excitement to
dermatologists and cosmetic, reconstructive, oral
and general surgeons and to their patients."
<P>BIOLASE announced that it will demonstrate the
DermaLase(TM) system to surgeons and dermatologists
on September 13th at the Ritz Carlton Hotel in
St. Louis. In preparation for what is expected
to be significant interest in the product,
the Company is currently interviewing various
distributors in appropriate markets and taking
measures to increase production volume. The Company'
intends to exhibit the DermaLase(TM)
system at various medical conferences throughout
the country during the next several months.
<P>BIOLASE Technology, Inc. manufactures and markets
advanced medical, dentaland surgical products,
including laser systems, HydroKinetic(TM) surgical
systems, specialized biomaterials for dentistry and
other medicalspecialties, and products for use in
endodontic applications. TheCompany's products
incorporate new patented and patent-pending
technologies that achieve results not available
through competing products.
The matters discussed in this news release
include forward lookingstatements which are
subject to various risks, uncertainties
other factors that could cause actual results
to differ materially from theresults anticipated
in such forward looking statements. Such risks,
uncertainties and other factors include, but
are not limited to, theeffect of actions of
third parties, including governmental officials,
the timely development and acceptance of new
products, the impact ofcompetitive products and
pricing, and other risks detailed fromtime-to-time
in the Company's filings with the Securities and
Exchange Commission, including the reports on
Forms 10-KSB and 10-Q. Actual results may
differ materially from those projected.
These forward-lookingstatements represent
the Company's judgment as of the date of this
release. The Company disclaims, however, any
intent or obligation toupdate these forward-looking
statements. <P>--30--jar/sf*
<P>CONTACT: Donald A. La Point
BIOLASE Technology, Inc. 714/361-1200
KEYWORD: CALIFORNIA <P>INDUSTRY KEYWORD: MEDICINE Today's News On The Net - Business Wire's fullfile on the Internet <P>with Hyperlinks to your home page. <P> URL: <A HREF="http://www.businesswire.com">http://www.businesswire.com</A> |
